The Role of FcRn in Antigen Presentation
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Immunoglobulins are unique molecules capable of simultaneously recognizing a diverse array of antigens and themselves being recognized by a broad array of receptors. The abundance specifically of the IgG subclass and the variety of signaling receptors to which it binds render this an important immunomodulatory molecule. In addition to the classical Fcγ receptors that bind IgG at the cell surface, the neonatal Fc receptor (FcRn) is a lifelong resident of the endolysosomal system of most hematopoietic cells where it determines the intracellular fate of both IgG and IgG-containing immune complexes (IgG IC). Cross-linking of FcRn by multivalent IgG IC within antigen presenting cells such as dendritic cells initiates specific mechanisms that result in trafficking of the antigen-bearing IgG IC into compartments from which the antigen can successfully be processed into peptide epitopes compatible with loading onto both major histocompatibility complex class I and II molecules. In turn, this enables the synchronous activation of both CD4(+) and CD8(+) T cell responses against the cognate antigen, thereby bridging the gap between the humoral and cellular branches of the adaptive immune response. Critically, FcRn-driven T cell priming is efficient at very low doses of antigen due to the exquisite sensitivity of the IgG-mediated antigen delivery system through which it operates. FcRn-mediated antigen presentation has important consequences in tissue compartments replete with IgG and serves not only to determine homeostatic immune activation at a variety of sites but also to induce inflammatory responses upon exposure to antigens perceived as foreign. Therapeutically targeting the pathway by which FcRn enables T cell activation in response to IgG IC is thus a highly attractive prospect not only for the treatment of diseases that are driven by immune complexes but also for manipulating local immune responses against defined antigens such as those present during infections and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
the Immunological Genome Consortium, Gautier, E. L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2419 · Cited by 1,972
Regulation of Phagosome Maturation by Signals from Toll-Like Receptors
Blander, J. M., & Medzhitov, R. (2004) · Science · doi:10.1126/science.1096158 · Cited by 991
Tamoutounour, S., Guilliams, M., Montanana Sanchis, F., Liu, H., Terhorst, D., Malosse, C., Pollet, E., Ardouin, L., Luche, H., Sanchez, C., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.004 · Cited by 783
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640 · cited 1×
“Indeed, the other well-known role for FcRn, protecting its serum ligands (IgG and albumin) from catabolism via recycling, is an important process ongoing throughout life (68, 69).”
BackgroundCrowley, M. T., Costello, P. S., Fitzer-Attas, C. J., Turner, M., Meng, F., Lowell, C., Tybulewicz, V. L. J., & DeFranco, A. L. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1027 · Cited by 506
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Leach, J. L., Sedmak, D. D., Osborne, J. M., Rahill, B., Lairmore, M. D., & Anderson, C. L. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.8.3317 · Cited by 348
Firan, M., Bawdon, R., Radu, C., Ober, R. J., Eaken, D., Antohe, F., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.8.993 · Cited by 330
Cited by
Overview of General and Discriminating Markers of Differential Microglia Phenotypes
Jurga, A. M., Paleczna, M., & Kuter, K. Z. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00198 · Cited by 1,000
Kasperkiewicz, M., Ellebrecht, C. T., Takahashi, H., Yamagami, J., Zillikens, D., Payne, A. S., & Amagai, M. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.26 · Cited by 523
Dendritic cell biology and its role in tumor immunotherapy
Wang, Y., Xiang, Y., Xin, V. W., Wang, X.-W., Peng, X.-C., Liu, X.-Q., Wang, D., Li, N., Cheng, J.-T., Lyv, Y.-N., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00939-6 · Cited by 453
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation
Junker, F., Gordon, J., & Qureshi, O. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01393 · Cited by 219
Wilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200
“It is involved in the bidirectional transcytosis of IgG and IgG immune complexes across various human epithelia (43–45), and its expression in hematopoietic cells (46, 47) is essential for the enhancement of IgG-mediated phagocytosis (48), anti-tumor immunosurveillance (49), and the direction of immune complexes to ly…”
Distribution of FcRn Across Species and Tissues
Latvala, S., Jacobsen, B., Otteneder, M. B., Herrmann, A., & Kronenberg, S. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417705095 · Cited by 178
“High and rather ubiquitous levels of FcRn expression have also been detected in professional APCs, where FcRn directs IgG-containing immune complexes toward MHC.(18) The importance of bone marrow–derived cells for IgG homeostasis has been shown in chimeric mouse studies, in which mice with FcRn-deficient bone marrow h…”
BackgroundMulti-angle effector function analysis of human monoclonal IgG glycovariants
Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143520 · Cited by 101
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundTargeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
Gjølberg, T. T., Mester, S., Calamera, G., Telstad, J. S., Sandlie, I., & Andersen, J. T. (2025) · BioDrugs · doi:10.1007/s40259-025-00708-2 · Cited by 20
Sirina, J., D'Hooghe, L. E., Singhvi-Hanns, L. A., Cole, S. L., Shock, A., Holliday, N. D., & Stoddart, L. A. (2026) · Cellular Immunology · doi:10.1016/j.cellimm.2026.105128
Metadata
- Authors
- Baker, K., Rath, T., Pyzik, M., & Blumberg, R. S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-08-27
- Volume
- 5
- Pages
- 408-408
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2126825171
- Cited by
- 121
- References
- 17
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.